The Relationship Between Cannabis Use Disorder and Affective Disorders
As the prevalence of cannabis use continues to rise, fueled by both legal markets and increased potency, understanding the health risks associated with cannabis has never been more critical. The level of THC in cannabis has significantly increased over the last half-century, leading to concerns about the potential for more severe health effects.
While the link between cannabis use and psychiatric conditions is well-established, the causal relationship is complex and often intertwined with various confounding factors. Recent research has shed light on the association between cannabis use disorder (CUD) and psychotic conditions, but less is known about its connection to affective disorders.
A study conducted by researchers from Denmark, Australia, and the US utilized extensive data to investigate the relationship between CUD and subsequent diagnoses of unipolar depression and bipolar disorder.
The increased presence of THC content in cannabis emphasizes the need to understand the health risks associated with cannabis use.
Methods
This study analyzed nationwide Danish register data spanning from 1995 to 2021, encompassing a large sample of individuals aged 16 and above. The dataset included information on CUD diagnoses, affective disorders, substance use disorders, demographics, and parental data, which were used to assess the risk of developing affective disorders following a CUD diagnosis.
Results
The study included over 6.6 million individuals, with 0.9% diagnosed with CUD and 3.9% developing affective disorders. Individuals with CUD were found to have a significantly higher risk of developing unipolar depression and bipolar disorder compared to those without CUD, even after adjusting for other factors.
The highest risk of developing these affective disorders occurred within the first 6 months post-CUD diagnosis, but the elevated risk persisted for up to 10 years.
Relative to those with no cannabis use disorder, those with a diagnosis were significantly more likely to develop unipolar depression or bipolar disorder.
Conclusions
The study’s key findings indicate that individuals with CUD face an increased risk of developing unipolar depression and bipolar disorder, with the highest risk observed in the first 6 months post-diagnosis, underscoring the importance of early intervention.
Implications for Practice
These findings have significant implications for clinical practice and public health policy. As cannabis use becomes more prevalent, efforts to address CUD and its associated mental health risks must be prioritized. Early intervention, integrated treatment approaches, prevention strategies, and harm-reduction initiatives are crucial to mitigating the adverse effects of cannabis use.
Healthcare providers, policymakers, and advocacy groups play a vital role in educating the public about the risks of cannabis use and promoting strategies for safe consumption. By raising awareness and implementing evidence-based interventions, we can better protect individuals from the negative consequences of cannabis-related disorders.
Policymakers and clinicians need to communicate associated risks and effective harm-reduction strategies with people affected by cannabis use disorders.
Strengths and Limitations
The study’s strengths lie in its large sample size, longitudinal design, and focus on the temporal relationship between CUD and affective disorders. However, limitations include reliance on psychiatric registry data, which may underrepresent individuals who do not seek treatment, and the unique context of the Danish population, which may limit generalizability to other regions.
Overall, while this research provides valuable insights into the link between CUD and affective disorders, further studies are needed to confirm and expand upon these findings in diverse populations.
Statement of Interests
No conflicts of interest to declare.
References
Primary Paper
Jefsen OH, Erlangsen A, Nordentoft M, Hjorthøj C. (203) Cannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder. JAMA Psychiatry. 2023;80(8):803–810. doi:10.1001/jamapsychiatry.2023.1256
Other References
World Drug Report (2023). United Nations.
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021). Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction, 116(5), 1000-1010.
Petrilli, K., Ofori, S., Hines, L., Taylor, G., Adams, S., & Freeman, T. P. (2022). Association of cannabis potency with mental ill health and addiction: a systematic review. The Lancet Psychiatry, 9(9), 736-750.
VICE (2019). Weed Is Way Stronger Than It Used to Be. That’s Why It Should Be Legal. https://www.vice.com/en/article/pa7anb/why-weed-should-be-legal-its-getting-stronger-more-potent
Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration.
Nordentoft M, Krantz MF, Hageman I. Right-Based Mental Health Care—Advantages of Tax-Financed Universal Mental Health Care: Lessons From Denmark. JAMA Psychiatry. 2022;79(1):7–8. doi:10.1001/jamapsychiatry.2021.3167
Wiktorowicz, M., Abdulle, A., Di Pierdomenico, K., & Boamah, S. A. (2019). Models of concurrent disorder service: policy, coordination, and access to care. Frontiers in Psychiatry, 10, 430489.
Fischer, B., Russell, C., Sabioni, P., van den Brink, W., Le Foll, B., Hall, W., Rehm, J., & Room, R. (2017). Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American journal of public health, 107(8), e1–e12.
